I read some interesting info (of which only a small extract is copied by me here) on a recent tweet from Dr Sarah Mackie - which I was not able to copy or upload a link to share - but for those who also follow her on Twitter no doubt they can find the full doc in her feed.
[it was prefaced by these comments:
'Come and talk to us about TARGET: our MRC-funded partnership between clinicians, scientists, industry to improve outcomes for patients with giant cell arteritis #GCA']
She is writing about a TARGET CONSORTIUM forum for clinicians, scientists, industry and patients to collaborate in research that improves outcomes for patients with giant cell arteritis, and reduces the burden of steroid toxicity'.
To do this she states they will use 'data analytics' - 'The Leeds Bioinformatic Centre will provide access to omic and e-health data' ... 'with clinical data from patients with GCA from 49 centres across England'
this document among other things states that:
'GCA 'is the most common form of systemic vasculitis'
'up to 75,000 people in the UE and US are identified with it each year'
'it is hard to diagnose because different patients experience varied and sometimes ambiguous symptoms'
'clinicians struggle to manage the balance between the long term cumulative toxicity of corticosteroid therapy, against the fact that steroids suppress inflammation and can enable patients to continue their everyday functions'
'not all patients respond to steroid therapy in the same way, some respond well and recover quickly, but others endure high doses of steroids for a number of years'
'the first biologic therapy has recently been licensed in the UK and EU so there is an even more pressing need for rapid, accurate diagnostics and patient stratification tools as well as better use of clinical data'
etc etc